We report the successful treatment of two acute lymphoblastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those used for the first allo-BMT. The patients relapsed on days 154 and 351 from the initial allo-BMT, respectively. Since conventional reinduction chemotherapy failed, allo-PBSCT was undertaken while the patients were still myelosuppressed immediately after reinduction chemotherapy. To induce and/or enhance GVL effects following allo-PBSCT, we performed rapid tapering of CsA and added DLI. After allo-PBSCT and DLI, the patients maintained their complete remission at 55 and 48 months post allo-PBSCT, respectively. From these findings, allo-PBSCT and DLI may be a useful treatment strategy for acute leukemia relapsing after allo-BMT. Bone Marrow Transplantation (2003) 31, 1057-1059. doi:10.1038/sj.bmt.1704059 Keywords: allo-PBSCT; DLI; relapse Relapse after allogeneic bone marrow transplantation (allo-BMT) for acute leukemia (AL) has been a crucial problem that affects the mortality rate of allo-BMT. One of the treatments for AL relapsed after allo-BMT is second allo-BMT. However, the prognosis of patients receiving a second allo-BMT is extremely poor. Transplant-related mortality within 100 days post second allo-BMT was reported to reach to 36-50%. Furthermore, it has been reported that the leukemia-free survival at 4 years posttransplant is only 11-21% among patients receiving a second allo-BMT.
Relapse after allogeneic bone marrow transplantation (allo-BMT) for acute leukemia (AL) has been a crucial problem that affects the mortality rate of allo-BMT. One of the treatments for AL relapsed after allo-BMT is second allo-BMT. However, the prognosis of patients receiving a second allo-BMT is extremely poor. Transplant-related mortality within 100 days post second allo-BMT was reported to reach to 36-50%. Furthermore, it has been reported that the leukemia-free survival at 4 years posttransplant is only 11-21% among patients receiving a second allo-BMT. 1, 2 Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) has been performed as an alternative therapeutic strategy to allo-BMT. [3] [4] [5] Recently, the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation have reported from a retrospective multivariate analysis that treatment-related mortality rate was lower and the leukemia-free survival rate higher with blood stem cell transplants than allo-BMT in patients with advanced leukemia, but not with early leukemia. 6 Donor lymphocyte infusion (DLI) has been reported to be an effective treatment for chronic myelogenous leukemia patients relapsing after allo-BMT. 7, 8 However, DLI seems to have no or little effect as a treatment for AL patients relapsing after allo-BMT, especially in acute lymphoblastic leukemia (ALL). One explanation is that the size of the tumor burden in AL patients may be larger than in CML. Based on this reasoning, a GVL effect because of DLI in AL may be more effective if the size of the tumor burden can be reduced.
In this report, we performed allo-PBSCT and DLI for the treatment of two ALL patients who had relapsed after allo-BMT. In brief, we performed allo-PBSCT from the same HLA-matched related donor as was used in the first allo-BMT, following conventional reinduction chemotherapy. When the development of acute GVHD (aGVHD) was not observed after the engraftment of hematopoietic cells, administration of CsA was terminated, if possible. Furthermore, if the onset of GVHD was not observed following the cessation of CsA, DLI were added to induce and/or enhance GVL effects.
Case report
A 34 year-old woman, was diagnosed with ALL (L2 in FAB classification, CD10 positive B-ALL) in January 1997. WBC were 315 000/mm 3 at diagnosis. She achieved complete remission (CR) with induction chemotherapy and underwent an allo-BMT from an HLA-identical sibling in June 1997. She experienced no clinical symptoms of GVHD and suffered a hematological relapse in November 1997. Duration of CR was only 154 days from the initial allo-BMT. She was given idarubicin and cytosine arabinoside, but failed to achieve CR. Even while she was still myelosuppressed following reinduction chemotherapy, 30% leukemic cells were still present in the bone marrow. Therefore, we performed an allo-PBSCT from the same donor as had been used for the initial allo-BMT in January 1998. The conditioning regimen consisted of BCNU (500 mg/mm 2 Â 1 day), etoposide (500 mg/mm 2 Â 3 days), and cyclophosphamide (60 mg/kg Â 2 days). The number of transplanted CD34-positive cells was 4.0 Â 10 6 /kg. We rapidly terminated CsA on day 14 following allo-PBSCT in order to induce and/or enhance the GVL effect. Since no aGVHD developed even after cessation of the CsA, we gave DLI on days 19, 33 and 47 (total number of CD3-postitive cells; 9.1 Â 10 7 /kg). Following DLI, aGVHD of grade II developed necessitating corticosteroid therapy. Although she experienced no further bone marrow relapse, she developed a pancreatic tumor because of an extramedullary relapse in September 1998 and received radiation therapy (30 Gy). She developed an extensive type of chronic GVHD (cGVHD), involving skin, eye, esophagus and muscle. To date, she has remained in CR for 55 months following allo-PBSCT (Table 1) .
A 24-year-old female with CD10-positive B-ALL in first CR underwent allo-BMT from her HLA-identical father in August 1997. aGVHD was not documented following the initial allo-BMT. Hematological relapse occurred in July 1998. Since two courses of reinduction chemotherapy (idarubicine+cytosine arabinoside, mitoxantron+cytosine arabinoside) failed to effect CR, allo-PBSCT was performed in August 1998 from the same donor as had been used initially. Conditioning was BCNU (500 mg/mm 2 Â 1day), Ara-C (2 g/mm 2 Â 2/day Â 3 days) and cyclophosphamide (60 mg/kg Â 2 days). The number of transplanted CD34-positive cells was 3 Â 10 6 /kg. CsA was stopped on day 18 following allo-PBSCT. Furthermore, DLI were given on days 54 and 92 (total number of CD3-positive cells; 5 Â 10 7 / kg). She developed aGVHD of grade I in the skin. She went on to develop cGVHD, involving the skin and liver, and has maintained in CR for 48 months following allo-PBSCT.
Discussion
Here, we described the successful treatment of two AL patients who relapsed after an allo-BMT and who received a second allo-PBSCT and DLI using the same donors as those used for the first allo-BMT. Since we used the same donors as for the first allo-BMT, the immunological background relating to HLA disparity should have been similar for the first allo-BMT and subsequent allo-PBSCT. The similar immunological background enables us to compare the effectiveness of the first allo-BMT with the subsequent allo-PBSCT. Early transplant-related mortality was not observed, and the duration of CR after the second allo-PBSCT was much longer than that after the first allo-BMT. Since there was resistance to reinduction treatment, these findings strongly suggest that our treatment protocol using allo-PBSCT and DLI has more potent antileukemic effects than allo-BMT.
It has been demonstrated that the size of the tumor burden influences the prognosis of patients receiving allo-BMT. Since CR could not be achieved by conventional reinduction chemotherapy in either case, we decided to perform the second allo-PBSCT while the patients were still myelosuppressed. Rapid hematological engraftment was observed and CR resulted in these patients even after reinduction failure. In addition, the toxicities associated with transplantation were not observed.
Collections of blood stem cells contain approximately 10 times more lymphocytes than bone marrow harvests. This could possibly influence immune reconstitution, as well as GVHD and GVL. In our cases, we were concerned about the safety of DLI immediately after allo-PBSCT. We infused the conventional number of CD3-positive cells for DLI that have been reported in the treatment of CML patients relapsing after BMT. 9 Although both cases developed an extensive type of cGVHD and one patient had reduced quality of life, life-threatening complications such as pancytopenia were not observed. From these data, standard doses of DLI could be safely administerd even immediately after the second allo-PBSCT. However, cell doses and schedules of DLI should be evaluated in further cases.
Recently, it has been reported that a high frequency of extramedullary relapse of acute leukemia is observed after allo-BMT. 10 One of the cases developed extramedullary relapse without marrow involvement following allo-PBSCT and DLI. From these reports and our experience, extramedullary sites seems to be unaffected by the immunological effects of approaches such as DLI. In other words, it is possible that the extramedullary sites, as compared with bone marrow, might be immunologically unaffected by the donor-derived cytotoxic T cells. However, this patient experienced CR of 34 months duration following radiation therapy. Although extramedullary relapse may be a problem, our treatment strategy could be effective for AL patients who have relapsed after allo-BMT. Furthermore, our treatment protocol could be used to treat advanced or high-risk leukemias receiving a first allogeneic stem cell transplant.
